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Rcl is a novel N-glycoside hydrolase found in mammals that
shows speciﬁcity for the hydrolysis of 50-monophosphate
nucleotides. Its role in nucleotide catabolism and the resulting
production of 2-deoxyribose 5-phosphate has suggested that it
might fuel cancer growth. Its expression is regulated by c-Myc,
but its role as an oncoprotein remains to be clariﬁed. In
parallel, various nucleosides have been shown to acquire pro-
apoptotic properties upon 50-monophosphorylation in cells.
These include triciribine, a tricyclic nucleoside analogue that
is currently in clinical trials in combination with a farnesyl-
transferase inhibitor. Similarly, an N6-alkyl-AMP has been
shown to be cytotoxic. Interestingly, Rcl has been shown to be
inhibited by such compounds in vitro. In order to gain better
insight into the precise ligand-recognition determinants, the
crystallization of Rcl with these nucleotide analogues was
attempted. The ﬁrst crystal structure of Rcl was solved by
molecular replacement using its NMR structure in combina-
tion with distantly related crystal structures. The structures
of Rcl bound to two other nucleotides were then solved by
molecular replacement using the previous crystal structure as
a template. The resulting structures, solved at high resolution,
led to a clear characterization of the protein–ligand inter-
actions that will guide further rational drug design.
Received 25 July 2012
Accepted 30 October 2012
PDB References: Rcl,
complex with phospho-
triciribine, 4fyh; complex with
6-cyclopentyl-AMP, 4fyi;
complex with adenosine
50-phosphorothioate, 4fyk
1. Introduction
Rcl is a putative oncoprotein and as such it may constitute a
new and attractive target for anticancer therapies. Its gene is
a c-Myc target and it has been shown to be overexpressed in
various cancers (Lewis et al., 2000). Rcl is responsible for
nucleotide hydrolysis and it produces free nucleobase and
50-phosphodeoxyribose, which is a strong elicitor of angio-
genesis (Ghiorghi et al., 2007). This may fuel cancer growth
while detoxifying the rapidly growing cells. However, a
stronger and more direct demonstration of the role of Rcl in
cancer development is still lacking. The design of potent
inhibitors may help in validating this hypothesis while opening
the road to mechanistic insights as well as potential future
treatments.
Although the solution structure of Rcl is known (Yang et al.,
2009), a more detailed view of the interactions between the
protein and its ligands is necessary for efﬁcient drug design.
Accordingly, we engaged in the determination of the crystal
structure of Rcl bound to purine monophosphate derivatives
(6-cyclopentyl-AMP, triciribine 50-monophosphate and
adenosine 50-phosphorothioate).
The ﬁrst crystal structure of rat Rcl was solved by molecular
replacement using a template derived from the NMR structure
of Rcl and distantly related proteins for which crystal struc-
tures are known but that show only low levels of sequence
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identity (20%). Solution of the ﬁrst crystal structure of Rcl
opened the road to the rapid determination of structures of
this protein bound to two other ligands. Here, we describe the
high-resolution structure of Rcl in complex with two chemical
compounds of high biological relevance, 6-cyclopentyl-AMP
(hereafter referred to as C6P) and phosphotriciribine (here-
after referred to as TCN-P), as well as adenosine 50-phos-
phorothioate (hereafter referred to as AMPS). C6P has been
shown to induce apoptosis through an unknown mechanism
(Mlejnek & Dolezel, 2005), while TCN-P is the monophos-
phorylated form of TCN, a drug candidate currently in clinical
trials in combination with a farnesyltransferase inhibitor
(Balasis et al., 2011). Recently, direct interactions of TCN-P
with the PH domain of Akt have been demonstrated and have
been shown to induce the relocalization of Akt, a protein
kinase involved in cell survival (Berndt et al., 2010). This may
explain the impact of TCN-P on cancer growth, but our results
suggest that Rcl could be another relevant target in vivo.
Finally, another crystal structure was solved in the presence of
the substrate mimic AMPS.
These structures highlight subtle changes in the active site
that cannot be easily detected by NMR. Conversely, NMR and
X-ray crystallography agree on the important ﬂexibility of
the long and central loop (residues 47–59). We discuss the
impact of the high-resolution structure on the analysis of the
proposed reaction mechanism as well as the design of better
inhibitors.
2. Experimental procedures
Initial crystallization trials were performed using a Tecan
Genesis crystallization robot equipped with eight independent
needles and a liquid-detection system. For crystallization,
96-well plates were used with the Anions, pHClear and
AmSO4 Suites from Qiagen. The wells were ﬁlled with 75 ml
crystallization buffer, and 0.5 ml crystallization buffer was
mixed with 0.5 ml of the protein sample (at 22 mg ml1 in
50 mM phosphate buffer pH 7.2 and 4 mM GMP) prior to
deposition at the drop location. The plate was then sealed with
transparent plastic ﬁlm (Greiner G-676070) and kept at 291 K.
Several hits were obtained but with poor crystal quality; those
corresponding to high concentrations of salts (1.6M ammo-
nium sulfate, HEPES pH 7 and Tris pH 8) were further reﬁned
manually using the hanging-drop method in 24-well plates.
Firstly, we successfully tested replacement of the phosphate
buffer by citrate buffer. The protein was dialyzed against
50 mM citrate buffer pH 7.3, concentrated in a Centricon and
mixed at 12 mg ml1 with 4 mM GMP. In the screen, the
precipitant (ammonium sulfate) concentration varied from 1.0
to 2.0M and the pH varied from 7.0 to 8.5. In this case, the
wells were ﬁlled with 0.5 ml crystallization buffer, and 1 ml
crystallization buffer was mixed with 1 ml protein sample prior
to deposition at the drop location. Starting from selected
conditions (those with the best crystal quality), further
reﬁnement was performed with 1.1, 1.2 and 1.3M ammonium
sulfate and 1.2, 1.3 and 1.4M lithium sulfate in mild basic
buffer (100 mM Tris pH 7.4–8.6) with 20 mM of one of the
following additives: ethanolamine, magnesium sulfate, 1,6-
hexanediol or 1,2,3-heptanetriol. These screening conditions
were used for cocrystallization assays with various ligands
including GMP, 6-cyclopentyl-AMP (C6P), triciribin phos-
phate (TCN-P) and adenosine 50-phosphorothioate (AMPS).
The crystals were cooled in liquid nitrogen and those obtained
in the presence of C6P, TCN-P or AMPS diffracted to up to
1.6 A˚ resolution on the synchrotron beamlines at the ESRF,
Grenoble.
Diffraction data were collected on beamlines ID14-4,
ID14-2 and ID29 at the ESRF, integrated using MOSFLM
(Leslie, 2006) and merged using SCALA from the CCP4 suite
(Winn et al., 2011). The reciprocal-space parameters and the
systematic absences corresponded to space group P21212.
Molecular replacement was performed using MOLREP
(Vagin & Teplyakov, 2010). Rigid-body and restrained
reﬁnement were performed using REFMAC5 (Murshudov et
al., 2011) with alternating manual rebuilding in Coot (Emsley
& Cowtan, 2004).
3. Results
3.1. An engineered variant of Rcl
Previous NMR studies of rat Rcl in complex with GMP
(Yang et al., 2009) and in the apo form (Doddapaneni et al.,
2009) revealed a well folded core and several regions with
poorly deﬁned conformations. The ﬂexible regions mainly
include the N- and C-terminal tails and a 12-residue-long loop
between 2 and 2 in the central portion of the protein (amino
acids 47–59 in rat Rcl). Sequence comparison of close ortho-
logues from mammals showed rapid divergence of both
terminal tails, while the internal disordered region was rather
well conserved. This is in agreement with the positions of these
segments relative to the active site. Indeed, both protein ends
are far away from the ligand-binding site, while the ﬂexible
loop 47–59 lies at the entrance to the active-site cavity. This
suggested that we could remove the ﬂexible tails but not the
central loop in order to engineer a variant of a mammalian Rcl
useful for crystallization.
At the same time, it has also been shown by NMR and
SAXS that unbound Rcl is in an equilibrium between a
monomeric and a dimeric form (Yang et al., 2009). This
behaviour is likely to hinder crystallization of Rcl. According
to SAXS measurements, Rcl forms a stable dimer upon the
addition of GMP. However, NMR studies showed slow
hydrolysis (on an hour time scale) of GMP and dissociation of
the protein dimer (Yang et al., 2009). These results could
explain the failure to grow useful crystals of Rcl in previous
attempts.
This information prompted us to (i) use a shortened rat Rcl
and (ii) design inactive mutants of this variant to attempt
crystallization. The N-terminal sequence MAASGEQAPC
was changed to MRR in order to remove the ﬂexible segment
and also to remove the cysteine to avoid the formation of
unwanted interchain disulﬁde bridges over time. Similarly,
the C-terminal sequence PQKTASSSHPSAwas removed and
replaced by the polyhistidine tag VEHHHHHH (see Fig. 1).
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Subsequently, the aspartate involved in catalysis (Asp69 in rat
Rcl) was substituted by either an asparagine (a conservative
substitution) or an alanine. Both mutants behaved like the
full-length construct in solution but with increased stability of
the dimeric form over several weeks in the presence of GMP
(Yang et al., 2009).
For the crystallization trials, we decided to use the most
conservative mutant (shortened rat Rcl D69N) in order to
better model possible interactions with the ligands. Optimal
crystal-growth conditions were searched for using 96-well
plates and a nanodispenser robot. Crystals were obtained in
conditions with various salts and pH values in the presence of
either GMP or C6P. We were able to improve the size and the
diffraction quality of the crystals by manual reﬁnement
around the starting conditions in the case of cocrystallization
with C6P. Crystals grown with GMP were mostly thin needles
and did not lead to satisfactory diffraction patterns. In order
to rapidly explore the potential crystallization of rat Rcl with
other inhibitors, a focused 48-condition screen was set up. The
main precipitant was either lithium sulfate (1.2–1.4M) or
ammonium sulfate (1.1–1.3M). This focused screen yielded
crystals of Rcl in the presence of TCN-P and AMPS. The
crystals of the shortened and stabilized Rcl in the presence of
C6P, TCN-P or AMPS diffracted to up to 1.6 A˚ resolution.
3.2. Solving the Rcl structure by molecular replacement
High-resolution diffraction data were collected on beamline
ID14-4, processed usingMOSFLM (Leslie, 2006) and merged
using SCALA from the CCP4 suite (Winn et al., 2011) from a
crystal grown at high salt concentration in the presence of the
ligand C6P. The unit-cell parameters, merging statistics and
systematic absences were consistent with space group P21212.
The calculated Matthews coefﬁcient (VM = 2.3 A˚
3 Da1)
suggested that four monomers were present in the asymmetric
unit, possibly forming two biologically relevant dimers (with
a solvent content of 46%). Knowledge of the dimeric forms
observed using NMR and SAXS was expected to help in
molecular replacement. However, the detection of pseudo-
translation suggested potential difﬁculties. Indeed, the
liganded NMR structure (PDB entry 2klh; Yang et al., 2009)
alone did not yield a solution for molecular replacement using
either MOLREP (Vagin & Teplyakov, 2010) or Phaser
(McCoy et al., 2007), which is in agreement with the general
trend for medium-resolution NMR structures (Mao et al.,
2011; DiMaio et al., 2011). In parallel, fold-recognition was
performed to identify possible templates for comparative
modelling using @TOME-2 (Pons & Labesse, 2009). Owing to
the low level of sequence identity (20%) with known but
distantly related crystal structures (PDB entries 1f8x, 2f62 and
3ehd; Armstrong et al., 1996; Bosch et al., 2006; Midwest
Center for Structural Genomics, unpublished work), no
molecular-replacement solution was detected using dimeric
models derived from models of Rcl based on these structures.
The known NMR structure of Rcl was used to guide a
realignment of its sequence with those of distantly related
proteins for which crystal structures are known. The manual
reﬁnement was performed using the software VITO (Cathe-
rinot & Labesse, 2004) in order to connect sequence alignment
and three-dimensional structure while surveying the common
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Figure 1
Sequence–structure alignment. The structural alignment of the NMR structure of Rcl and the sequence alignment deduced from fold-recognition using
@TOME-2 (Pons & Labesse, 2009). Secondary structures in Rcl are shown above the sequence alignment. Well conserved residues are boxed and strictly
conserved residues are shown in white on black. The black stars and grey circles indicate the positions of the residues removed in the recombinant
variant of Rcl and those removed in the model for molecular replacement, respectively. This ﬁgure was generated by the ESPript server (Gouet et al.,
1999).
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dimeric interface. The main goal was to deﬁne a structural
core common to both the NMR structures and the distantly
related crystal structures in order to better deﬁne a useful
template for molecular replacement. While minor changes
were made to short segments mostly corresponding to small
loops in the N-terminal and central parts of the structural
alignment, some important changes were performed in the
region corresponding to the last 50 residues (see Fig. 1). This
part included the last -strand (5) and the very C-terminal
-helix (5). This segment is highly variable in sequence,
although it is partially constrained by a common dimeric
interface observed in all of the distantly related structures (e.g.
PDB entries 3ehd and 1f8x) as previously described by Yang et
al. (2009). Indeed, fold-recognition provided us with a struc-
tural alignment that varies greatly in this region, with only
FUGUE (Shi et al., 2001) correctly aligning strand 5, while
helix 5 was not correctly aligned. The revised sequence–
structure alignment was used to derive new models of Rcl
based on the conserved parts shared with the related crystal
structures. The ﬁnal models were built using SCWRL4.0
(Krivov et al., 2009) for each monomer and were subsequently
combined as dimers. Finally, the long and mobile loop (amino
acids 47–59) as well as the C-terminal histidine tag were
omitted from the model.
We then searched for two dimers using the program
MOLREP. A weak solution was obtained (contrast 2.1; R
factor 63.1). Following ten steps of rigid-body reﬁnement in
REFMAC5 (Rwork = 0.543, Rfree = 0.564), restrained reﬁne-
ment (with NCS restraints) led to smooth minimization and
improvement of the working and free R factors (to 0.503
and 0.558, respectively). The electron density for the bound
nucleotide was partially visible although it was omitted from
the search model. Additional steps of restrained minimization
were performed varying the high-resolution limit (from 2.96 to
1.96 A˚) and subsequently lowering the NCS restraints (from
tight to medium). This led to a signiﬁcant decrease in the
working and free R factors (to 0.443 and 0.517, respectively).
Then, thanks to the recording of high-resolution data and the
known NMR structure, complete rebuilding and straightfor-
ward reﬁnement could be performed. Alternating manual
rebuilding in Coot (Emsley & Cowtan, 2004) and restrained
reﬁnement with looser NCS restraints in REFMAC5
(Murshudov et al., 2011) led to a satisfactory and almost
complete model. The overall improvement can be witnessed in
the C-terminal region (see Figs. 2a and
2b), in which manual alignment reﬁne-
ment was important for successful
molecular replacement and easier
model rebuilding. Finally, restrained
reﬁnement with TLS (Winn et al., 2001)
with no NCS restraints resulted in a
high-quality structure (Rwork = 0.188,
Rfree = 0.230; see Table 1).
3.3. Comparison of the crystal and the
solution structures
Although the structures of Rcl solved
by NMR (PDB entries 2klh and 2khz;
Doddapaneni et al., 2009) and X-ray
diffraction are globally very similar (Fig.
3a), the overall r.m.s.d. was quite high
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Figure 2
Comparison of the electron densities before and after reﬁnement. (a) Local view of the partial
model used for molecular replacement and the corresponding electron-density map drawn around
the side chains of Ile32, Leu107, Leu143 and Trp132. This region includes segments that were
correctly aligned automatically (e.g. helix 1) and segments that required manual reﬁnement (e.g.
helix 5). (b) The same region shown after ﬁnal reﬁnement with a much better match of the model
to the electron density. The ﬁgures were generated using PyMOL (http://www.pymol.org).
Table 1
Data-collection, phasing and reﬁnement statistics for the Rcl structures.
Values in parentheses are for the outer shell.
Rcl–C6P Rcl–TCN-P Rcl–AMPS
Beamline ID14-4 ID14-2 ID29
No. of crystals 1 1 1
Space group P21212 P21212 P21212
Unit-cell parameters
a (A˚) 91.6 92.7 86.4
b (A˚) 119.0 118.7 128.8
c (A˚) 57.5 57.7 57.5
No. of molecules in
asymmetric unit
4 4 4
Wavelength (A˚) 0.97950 0.93340 0.97625
Resolution (A˚) 1.96 (2.01–1.96) 2.44 (2.50–2.44) 1.79 (1.84–1.79)
Rmerge† (%) 4.0 (22.9) 8.5 (37.6) 6.4 (13.3)
hI/(I)i 19.4 (5.3) 8.0 (1.9) 10.3 (4.5)
Completeness (%) 97.4 (96.8) 100.0 (100.0) 92.7 (68.1)
Multiplicity 8.0 (7.8) 7.2 (7.3) 3.2 (2.4)
Wilson B factor (A˚2) 24.2 38.1 16.1
Reﬁnement
Resolution (A˚) 42.5–1.96 38.9–2.60 35.9–1.79
No. of reﬂections 42198 23302 55536
Rwork/Rfree‡ (%) 18.1/21.7 20.9/24.6 19.6/21.9
No. of atoms
Protein 4790 4153 4790
Ligand 4 4 4
Ions — 5 3
Waters 404 123 626
B factors (A˚2)
Protein 24.1 26.9 15.8
Ligand 20.2 17.6 9.9
Ions — 58.9 44.1
Waters 35.5 28.8 35.7
R.m.s. deviations§
Bond lengths (A˚) 0.008 0.010 0.009
Bond angles () 1.3 1.1 1.1
†
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ  100. ‡ Rfree was calculated using a
subset of reﬂections that were not used in the reﬁnement (5%). § Deviations from
ideal values.
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(1.9 A˚ with PDB entry 2klh and 1.5 A˚ with PDB entry 2khz
over 125 residues forming the common core of a monomer).
The r.m.s.d. (computed in Coot) for the dimer increases to 2.3
and 1.7 A˚ with the solution structures (PDB entries 2klh and
2khz, respectively) and to 2.0 A˚ (over 208 C atoms) with the
crystal structure of the template (PDB entry 1f8y; Fig. 3b;
Armstrong et al., 1996). The dimerization interface and central
-sheet showed little difference, while two -helices (1 and
5, both of which are solvent-exposed) showed signiﬁcant tilts
or shifts (a translation of up to 3 A˚).
In agreement with the previously described structures of
Rcl in solution, the long loop (47–59) appeared to be disor-
dered, with only weak electron density visible in the vicinity of
the bound ligand. However, the electron density was too weak
to allow proper modelling of the missing residues. Similarly,
the ﬁrst two residues in the crystallized construct and the very
C-terminus (residues 149–154 and the polyhistidine tag)
appeared to be ﬂexible and were not modelled.
Further analysis indicated that differences appear in many
details. Firstly, the interactions between the protein and ligand
are better deﬁned (see below). Indeed, the precise orienta-
tions of several side chains in the active site are much better
deﬁned (e.g. Arg19), although one should keep in mind that
the crystal lattice and the crystal-growth conditions (high salt
concentration) might locally affect the protein structure. In
addition, many water molecules are also clearly observed in
the electron density, including in the vicinity of the bound
nucleotide.
3.4. A conserved catalytic mechanism in NDTs and Rcl
A search for similar structures using FATCAT (Ye &
Godzik, 2004) identiﬁed all of the NDTs solved to date, with
an r.m.s.d. (for the monomer) of around 2.5 A˚, and also the so-
called receiver domain, with a higher r.m.s.d. (above 3.0 A˚).
The latter matches correspond to conservation of the Ross-
mann fold, but no similarities in the active site can be found
and local rearrangements in the receiver domain close the
ligand-binding pocket found in NDT and Rcl. In parallel, the
global structural divergence of Rcl and NDT is correlated with
high sequence variation, while the catalytic centre seems to be
perfectly conserved. Nevertheless, signiﬁcant rearrangements
occurred, in agreement with the shift in substrate speciﬁcity
(50-monophosphorylated nucleotides for Rcl versus nucleo-
sides for NDTs). This change in function relies mainly on the
build-up of a phosphate-accommodating loop in Rcl. It is
composed of loop 1–1, which is longer in Rcl and adopts a
distinct conformation compared with the equivalent loops
in NDTs. In addition, several residue substitutions leave room
for the bulky phosphate group and simultaneously remove a
negative charge (see below).
In order to gain a better insight into the mechanism of
catalysis by Rcl, we focused our structure comparison on the
catalytic centre of Rcl and the NDTs. The catalytic residues of
Rcl (Tyr13, Asp69 and Glu93 in rat Rcl) have previously been
identiﬁed using directed mutagenesis and sequence compar-
ison among mammalian Rcls and also with known NDTs
(Ghiorghi et al., 2007; Dupouy et al., 2010). The catalytic triad
in the crystal structure of Rcl adopts nearly the same orien-
tation despite the mutation of the aspartate Asp69 to aspar-
agine. In all three Rcl structures solved to date, these three
residues occupied positions nearly identical to those observed
for the catalytic residues in the NDT structures (hr.m.s.d.i =
0.45 A˚). For both NDTs (Armstrong et al., 1996; Anand et al.,
2004) and Rcl (this study), the crystal structures show that
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Figure 3
Comparison of solution and crystal structures. (a) The crystal structure (green ribbon) of rat Rcl in the dimer (this study) is shown superposed on its
solution structure determined in the presence of GMP (PDB entry 2klh; blue). (b) Superimposition of rat Rcl (green ribbon) with a crystal structure of a
distantly related nucleoside 2-deoxyribosyltransferase (PDB entry 1f8y; violet). In all cases, ligands were omitted for clarity. The ﬁgures were generated
using PyMOL (http://www.pymol.org).
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these three residues form an intricate network of hydrogen
bonds that also involves the bound ligand (if present). The
perfect geometric conservation of this triad suggested that
these enzymes share a similar mechanism of action. In NDT
from Lactobacillus leichmannii, the catalytic glutamate
(Glu98) has been shown to be the active-site nucleophile
(Porter et al., 1995) and a ribosylated enzyme intermediate
involving an equivalent glutamate (Glu101) has been trapped
using 2-deoxy-2-ﬂuoro derivatives (Anand et al., 2004). In
NDTs and in Rcl the carboxylate group of the catalytic
glutamate is at a close distance to the C10 atom of the ribose
moiety. This suggested that this residue can also attack the C10
atom of the ribose to form a ribosylated enzyme. As in NDTs,
this glutamate interacts with a tyrosine (Tyr13) and an
aspartate (Asp69) in wild-type Rcl. These two residues are
supposed to stabilize the different states of the glutamate
residue in NDTs and, by similarity, in Rcl. In agreement with
these hypotheses, conservative mutations (Y13F, D69N or
E93Q) in Rcl abolish the activity or dramatically decrease the
afﬁnity for the substrate (Dupouy et al., 2010).
Interestingly, Rcl is purely a hydrolase, while the distantly
related NDTs are mainly transferases. In NDT, reaction
proceeds by transfer of the deoxyribose moiety from the
ribosylated enzyme intermediate to an acceptor nucleobase
(Short et al., 1996). In Rcl, in contrast, this transfer step
involves a solvent molecule, as demonstrated by a methano-
lysis study (Doddapaneni et al., 2011). A survey of the various
NDT structures in unbound, substrate-bound and ribosylated
forms shows that very few water molecules can occupy the
ligand-binding sites. The very few water molecules found in
the apo form of NDT from L. leichmannii (PDB entry 1f8x)
occupy the positions of the 30-hydroxyl group of the ribose or
polar atoms of the nucleobase found in the bound state (PDB
entry 1f8y). In the ﬁrst case, the water molecule cannot enter
into the ribosylated intermediate state. In the second case, the
water molecules may be too distant to attack and free the
ribosyl moiety. The absence of attacking water may correlate
with the rather hydrophobic nature of the ligand-binding
pocket. In NDTs, beside the catalytic triad, large aromatic
residues constitute the active site and it is rather closed by
various loops and the C-terminus. Conversely, the active site in
Rcl appears to be largely open as the loop 47–59 is disordered.
Furthermore, we observed two water molecules in the vicinity
of the bound ribose, while the presence of the hydrophobic
side chain of a proline (Pro42 and Pro44 in the NDTs from
L. leichmannii and L. helveticus, respectively) prevents solvent
entrance in NDTs (Fig. 4). In addition, the preference for
solvent attack over nucleobase substitution may correlate with
weaker interactions between the Rcl binding site and the
nucleobase (see below).
3.5. Ligand recognition in the C6P-bound Rcl
In the crystal structure of Rcl in complex with C6P, the
position of the inhibitor in the active site is clear (Fig. 5a). The
adenine, ribose and phosphate moieties are very well deﬁned
in the electron density, while the 6-cyclopentyl moiety appears
to be mobile or in an alternative conformation in the four
independent monomers (data not shown). The new crystal
structure clariﬁed the position of the phosphate group and the
orientations of the phosphate O atoms.
Previously, in the NMR structure, the
phosphate group was not directly posi-
tioned but was predicted to form
hydrogen bonds according to low-ﬁeld
chemical shifts of the backbone N atoms
of three residues (Ile18, Arg19 and
Ala118). The orientation of the side
chain of Arg19 is also better deﬁned in
the crystal structure compared with the
NMR structures and showed a
surprising feature. The positively
charged guanidinium group did not
point toward the negatively charged
phosphate group. Rather, it points
towards a nearby aspartate (Asp62) to
form a salt bridge (distance of 3.9 A˚),
forming a lid over the phosphate group
(Fig. 5d). It also appeared to stabilize
the dimer and the ligand-binding site
through a hydrogen bond to the
carbonyl of Leu1160. The arginine also
weakly interacts with the 6-cyclopentyl
group of the ligand. In parallel, the
crystal structure revealed an intricate
network of seven hydrogen bonds
formed between the phosphate group
research papers
252 Padilla et al.  Rcl Acta Cryst. (2013). D69, 247–255
Figure 4
NDT and Rcl catalytic triads. (a) Superimposition of the catalytic triad from liganded NDT
structures (PDB entries 1f8y, 1s2g and 1s3f; Anand et al., 2004). The catalytic residues and the
bound ligand are shown as a wireframe in CPK colours. In addition, a neighbouring proline that
prevents the entrance of water molecules into the active site (Pro44 in L. helveticus and Pro442 in
L. leichmannii) is shown. (b) Catalytic triad in Rcl structures. Red spheres show water molecules in
the vicinity of the ribose from the three structures. The ﬁgures were generated using PyMOL (http://
www.pymol.org).
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and the protein (Fig. 5d) that involves the side-chain hydroxyl
groups from two serines (Ser87 and Ser1170), the backbone N
atoms of Ile18, Arg19, Gly20, Gly89 and, indirectly, Ala1180
(through a water molecule). The same water molecule is
hydrogen-bonded to the N7 atom of the adenine moiety. This
intricate network of hydrogen bonds results in tight recogni-
tion of the phosphate group and this may explain the strong
speciﬁcity of Rcl for monophosphated nucleotides compared
with 50-sulfated analogues, as described previously (Dupouy et
al., 2010). In parallel, the ribose interacts with Gly16, Gly89,
Glu93 and Met1190. The latter protrudes from a second
monomer and forms short van der Waals contacts with the O40
and C10 atoms of the ribose (C—O40 and C—C10 distances
of 3.2 and 3.7 A˚, respectively). The O40 atom is also in van der
Waals contact with the C atom of Gly89 (distance of 4.0 A˚),
while the N atom of Gly16 is hydrogen-bonded to the O30 atom
of the ribose. The two hydroxyls O20 and O30 are hydrogen-
bonded to the carboxylate group of the catalytic Glu93. The
O20 hydroxyl (O"1—O20 distance of 2.6 A˚) seems to attract
the carboxylate group of Glu93. Accordingly, the presence of
an additional hydroxyl group in a ribonucleotide may limit
attack at C10, and this would explain the observed inhibitory
activity of nucleoside monophosphates towards Rcl. Tyr13
also forms a hydrogen bond to the O"1 atom of the catalytic
glutamate and is expected to stabilize its orientation. The
neighbouring Asn69 (Asp69 in wild-type Rcl) shows a weak
interaction with C10 (N2—C10 distance of 3.5 A˚). However, in
the wild-type enzyme the negatively charged aspartate may
activate the hydrolysis of the N-glycosidic bond. The ribose
and phosphate moieties appear to be tightly bound in the
crystal structure. Conversely, the nucleobase seems to be
weakly bound, being sandwiched by only two hydrophobic
isoleucines (Ile18 and Ile65), although the neighbouring
Asn69 forms a weak hydrogen bond to the N3 atom (N2—N3
distance of 3.1 A˚). This situation implies little speciﬁcity in
nucleobase recognition, which is in agreement with the
hydrolytic activity of Rcl towards a large spectrum of 20-
deoxynucleotides.
In conclusion, the crystal structure of Rcl–C6P conﬁrmed
and more precisely revealed the organization of its nucleotide-
binding site. It strongly suggests that large variations in the
nucleobase may be used to derive new inhibitors of this
therapeutic target. Furthermore, the binding of C6P, a pro-
apoptotic compound, to Rcl will fuel interest in this putative
oncoprotein. Our structure also revealed that Rcl could be
the actual target of various nucleotide analogues formed of
a phosphoribose moiety bearing a nucleobase-like moiety.
Several nucleosides are already in clinical use or under
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Figure 5
Crystal structures of complexes of Rcl with C6P (a, d), TCN-P (b, e) and AMPS (c, f). (a)–(c) Views of the 2Fo Fc electron-density map in the active site
with the ligand molecule omitted from the Fourier synthesis. The map is contoured at 0.9. (d)–(f) Alternative view of the binding site highlighting the
hydrogen-bond networks involved in the tight recognition of the phosphate/phosphorothioate groups. The ﬁgures were generated using PyMOL (http://
www.pymol.org).
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development and some may interact with Rcl after mono-
phosphorylation, as illustrated by TCN-P (see below).
3.6. Crystal structure of Rcl in complex with
phosphotriciribine
Among the nucleosides that are already in clinical use or
that are promising drug candidates for cancer therapy, we
selected triciribine as a potential inhibitor of Rcl in its
monophosphorylated form. Triciribine is currently under
clinical trials in combination with a farnesyltransferase inhi-
bitor (Balasis et al., 2011). However, the actual mechanism of
action of triciribine has yet to be unravelled, although its
binding to the PH domain of Akt represents an attractive
mechanism, as this protein kinase is important for cell survival
(Berndt et al., 2010).
Here, we present the crystal structure of Rcl in complex
with triciribine monophosphate (TCN-P). Crystals were
grown using the same method as used for the Rcl–C6P
complex. Data were collected on beamline ID14-2, integrated
and merged as for the Rcl–C6P structure (see Table 1). The
overall structure closely resembles that of C6P-bound Rcl.
The ribose was oriented similarly as in the Rcl–C6P complex.
The planar tricycle mimics the adenine moiety apart from the
extra ring linking positions N6 and C7 in triciribine (Fig. 5b).
The main variation occurred in the vicinity of the phosphate
group, where a nearby water molecule was replaced by the
amino group protruding from the additional ring. The amino
group is directly hydrogen bonded to an O atom of the
phosphate group (distance of 2.65 A˚). Concomitantly, the
side chain of Arg19 is observed in two alternating conforma-
tions. In one conformation it points towards Asp62 to form a
salt bridge as in the C6P complex, while in the other it points
towards the bulk solvent and the salt bridge with Asp62 is
broken (Fig. 5e). The intramolecular hydrogen bond and the
additional van der Waals contacts between the tricycle and the
sandwiching Ile18 and Ile65 (shortest distances of 4.1 and
3.6 A˚, respectively) may explain the higher afﬁnity of tricir-
ibine monophosphate compared with AMP (Ki of 14 versus
40 mM). This structure conﬁrmed the accommodation of larger
nucleobases in the active site of Rcl. The long and disordered
loop (47–59) remained highly ﬂexible in the new structure.
In conclusion, this structure revealed a change in the water
shell surrounding the phosphate group, suggesting the possi-
bility of subtle variations in an attempt to stabilize the bound
conformation of the nucleotide prior to binding and accord-
ingly lower the entropy cost of binding. Our structure also
conﬁrmed that triciribine might target Rcl in vivo upon its
phosphorylation.
3.7. Crystal structure of Rcl in complex with
adenyl-phosphorothioate
Phosphorothioate is currently used as a surrogate phos-
phate group in RNA molecules for therapeutic applications
and shows enhanced stability in vivo (owing to its resistance to
phosphatases) as well as improved membrane permeability.
We wondered whether this moiety could adequately mimic the
phosphate group despite the strong speciﬁcity of Rcl described
previously (Dupouy et al., 2010). AMPS has been shown to be
a micromolar inhibitor (14 mM) with a slightly better efﬁciency
than that of AMP (40 mM), while 50-sulfo-adenosine is a poor
inhibitor.
Here, we present the crystal structure of Rcl in complex
with phosphorothioate adenosine (AMPS). Crystals were
grown using the same method as used for the Rcl–C6P
complex. Data were collected on beamline ID29, integrated
and merged as for the above structure (see Table 1). We solved
the structure of Rcl bound to AMPS by molecular replace-
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Figure 6
Comparison of the ribose conformations. (a) Protein structures were
superposed in Coot and the ribose conformation or the position of the
nucleobase was analyzed. The shortest distances between C8 and an O (or
S) atom of the phosphate group are shown by dotted lines. (b) Histogram
of the distances observed between C8 and the closest O atom of the
phosphate group of either AMP or GMP found in the protein structure
deposited in the PDB (Berman et al., 2000).
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ment using the structure of the Rcl–C6P complex as a starting
template. The high resolution allowed clear identiﬁcation of
the position of the S atom in the electron density (Fig. 5c).
Again, as in the Rcl–TCN-P complex, the water molecule lying
between the phosphate group and the nucleobase is also
displaced in the new crystal structure. This resembles the
above structure solved with TCN-P, although in this case the
variation was provided by a different chemical modiﬁcation.
As in the previous complex, the presence of the phosphoro-
thioate also induced a change in the position of Arg19. The
guanidinium group of its side chain is now in close contact with
Asp62 as two hydrogen bonds are formed (N1—O1 and
N2—O2 distances of 2.8 A˚) and strengthen the salt bridge
(Fig. 5f). The crystal structure also revealed a signiﬁcant
change in the conformation of the nucleotide, with a slightly
more ‘opened’ ribose (Fig. 6a). This conformational rearran-
gement of the sugar moiety may be driven by the substitution
of an O atom by a larger S atom. Indeed, in the two previous
complexes a short distance is observed between an O atom of
the phosphate group and the C8 position of C6P or TCN-P
(3.45 and 3.29 A˚, respectively), while the equivalent distance
increases to 3.64 A˚ in the Rcl–AMPS complex. The observed
variations match the conformational variability observed in
the other AMP-bound protein complexes that we surveyed in
the PDB (Fig. 6b).
In conclusion, this structure revealed a subtle change in
the sugar conformation and the perfect accommodation of a
phosphorothioate in the active site of Rcl. This suggested a
slightly more ﬂexible deﬁnition of the pharmacophoric feature
in order to design new inhibitors with potentially improved
afﬁnity and/or better pharmacokinetic properties.
4. Discussion
In this study, we have combined information from an NMR
structure of Rcl and fold-recognition models in order to
crystallize and then solve the crystal structure of rat Rcl, a
putative oncoprotein. The crystal structures of the complexes
formed by Rcl with three distinct inhibitors were reﬁned to
atomic resolution. Among the three cocrystallized nucleotides,
two are already of interest in cancer therapy (Mlejnek &
Dolezel, 2005; Balasis et al., 2011). The precise orientation of
these ligands in the active site as well as the role of important
side chains was precisely determined. Similarly, the positions
of water molecules in the active site were deﬁned with high
accuracy. This structural information agrees well with func-
tional data obtained by means of enzymology and directed
mutagenesis (Ghiorghi et al., 2007; Dupouy et al., 2010).
The new crystal structures will help to guide the design of
improved inhibitors. Indeed, the tight recognition of the
phosphate group in the active site of Rcl suggests that only a
few substitutions will readily be accepted at the 50 position of
the nucleotide. Conversely, most positions on the nucleobase
appear to be amenable to large variations and substitution in
order to design better inhibitors. Chemical synthesis of new
ligands is currently in progress.
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